Core–shell formulations were first applied in anti-tumour combination medication therapy in Sengupta's ground-breaking study.18 The efficacy of core–shell lipid nanoparticles containing adriamycin and a P-glycoprotein inhibitor was subsequently shown,49 displaying significant inhibitory effects on adriamycin-resistant breast cancer cell lines. This evidence concerns the gene ABCB1 and breast carcinoma.